To hear about similar clinical trials, please enter your email below
Trial Title:
Combination of Local Therapy and Target Therapy for Brain Metastases With EGFR Mutation
NCT ID:
NCT05616377
Condition:
Brain Metastases
Conditions: Official terms:
Neoplasm Metastasis
Brain Neoplasms
Study type:
Observational
Overall status:
Not yet recruiting
Study design:
Time perspective:
Retrospective
Intervention:
Intervention type:
Other
Intervention name:
Surgery or Radiotherapy
Description:
Participants who underwent target therapy and surgery or radiotherapy were divided into
target therapy + local therapy group. Participants who underwent target therapy alone
were divided into target therapy alone group
Arm group label:
target therapy + local therapy group vs target therapy alone group
Intervention type:
Other
Intervention name:
before or after target therapy
Description:
Participants who underwent surgery or radiotherapy before target therapy were divided
into local therapy before target therapy group. Participants who underwent surgery or
radiotherapy after target therapy were divided into local therapy after target therapy
group.
Arm group label:
local therapy before target therapy group vs local therapy after target therapy group
Summary:
The goal of this observational study is to learn about the survival benefit of local
therapy combination with target therapy in lung cancer brain metastases with EGFR
mutation. The main questions it aims to answer are:
- Is local therapy performed before or after target therapy would provide survival
benefit ?
- What kind of local therapy combining with target therapy would provide survival
benefit, neurosurgical resection or radiotherapy?
Criteria for eligibility:
Study pop:
Hospital clients from Sun Yat-sen University Cancer Center, Guangxi Medical University
Cancer Hospital, The People's Hospital Of Guangxi Zhuang Autonomous Region, and the First
Affiliated Hospital of Guangxi Medical University will be selected.
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
1. Evidence of pathological diagnosis of primary tumor.
2. Brain metastases confirmed by enhanced magnetic resonance imaging.
3. Gene test indicated that EGFR mutation.
4. Complete clinical information.
Exclusion Criteria:
1. If surgical treatment is accepted, the surgical treatment is not tumor resection,
but ventricle puncture, biopsy and other non-tumor reducing surgery.
2. Patients with 2 or more types of tumors.
3. Incomplete clinical information.
Gender:
All
Minimum age:
N/A
Maximum age:
N/A
Healthy volunteers:
No
Start date:
November 20, 2022
Completion date:
November 20, 2024
Lead sponsor:
Agency:
Sun Yat-sen University
Agency class:
Other
Source:
Sun Yat-sen University
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05616377
